Carter T. Fields

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons et al. · Cancer Cell · 2009 · 822 citations · Full text

Molecular Pharmacology, Signaling Pathway, Medicine +10

Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and <i>IBD1</i>

Judy H. Cho, Dan L. Nicolae, Leslee H. Gold et al. · Proceedings of the National Academy of Sciences · 1998 · 383 citations

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

Gabriele Schaefer, Lauric Haber, Lisa Crocker et al. · Cancer Cell · 2011 · 332 citations · Full text

Immunocytochemical Technique, Allergy, Autoimmune Disease +9

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li et al. · Clinical Cancer Research · 2013 · 192 citations

Targeting LGR5 ⁺ cells with an antibody-drug conjugate for the treatment of colon cancer

Melissa R. Junttila, Weiguang Mao, Xi Wang et al. · Science Translational Medicine · 2015 · 173 citations

Tumor Biology, Csc Marker, Drug Targeting +14